🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life

Recruitingn/aAges 18 Years - anyAllCentre Hospitalier Régional d'Orléans
NCT07257861 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Care for Parkinson's patients at the end of life is far from optimal, particularly due to specificities linked to the disease itself, often unknown to non-specialists. A study carried out at the CHU Rennes on data covering the period 2006-2018 showed that only 132 patients died in this hospital, two-thirds of whom came from home. In 42% of cases, antiparkinsonian treatment was stopped before death without specialist advice (palliative or neurological), with the corollary of the appearance of a dopaminergic withdrawal syndrome (or pseudo-neuroleptic malignant syndrome) in a high proportion of these patients. Neuroleptic pseudo-malignant syndrome is a major cause of discomfort. If left untreated, it can precipitate death in particularly distressing conditions for the patient, his or her family and caregivers. The Rennes study also suggests that Parkinson's patients rarely die in hospital

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Person (or trusted person/relative if patient is unable) who has agreed to participate in the study 2. Patient of legal age 3. Advanced Parkinson's disease with apomorphine pump indication 4. Use of HH for palliative reasons 5. Loss of orality (discontinuation of oral treatments) 6. Hoehn \&Yahr score in OFF = 5 (bilateral and axial symptoms in the absence of levodopa) Exclusion Criteria: 1. Apomorphine pump already in use 2. Opposition to the introduction of an apomorphine pump 3. Protected person (under guardianship or curatorship) 4. Person under court protection 5. Persons deprived of liberty 6. Persons not affiliated to a social security scheme 7. Pregnant or breast-feeding woman
💊

What it tests

  • Questionnaires
📍

Where

1 site
Had Crest
Crest, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy